Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO) - Nature Communications
Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma Neoadjuvant chemoradiotherapy is the current standard treatment for patients with resectable locally advanced esophage…